Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma

Video

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.

Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
Related Content
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM

Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM

Targeted Oncology Staff
July 22nd 2024
Article

During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.

Read More

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Binod Dhakal, MD, MS;Jordyn Sava
June 14th 2024
Podcast

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma

Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma

Jordyn Sava
July 16th 2024
Article

Taiga Nishihori, MD, discussed the current outpatient administration model of cilta-cel among patients with relapsed/refractory multiple myeloma.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

Jordyn Sava;Ben Derman, MD
February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Deep and Durable Responses: Ide-Cel CAR T Shows Promise for High-Risk Multiple Myeloma Relapse

Deep and Durable Responses: Ide-Cel CAR T Shows Promise for High-Risk Multiple Myeloma Relapse

Ariana Pelosci
July 4th 2024
Article

A cohort study of the KarMMa-2 trial discovered durable responses in patients with high-risk multiple myeloma treated with ide-cel.

Read More

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

Sabrina Serani
July 2nd 2024
Article

The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.

Read More